Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | GHSR | Q92847 | 10/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2116921 | 0.80 | THRB (0.45) | MEN1ALDH1A1KMT2AMAPTPKM | |
| SCHEMBL2119729 | 0.77 | ALDH1A1 (0.49) | MEN1ALDH1A1KMT2AKDM4EMAPT | |
| SCHEMBL2119329 | 0.74 | GHSR (0.45) | MEN1ALDH1A1KMT2AKDM4EMAPT | |
| SCHEMBL2118158 | 0.73 | ACLY (0.55) | SMN1; SMN2 | |
| SCHEMBL2117726 | 0.73 | P2RX7 (0.40) | MEN1ALDH1A1KMT2AKDM4EMAPT | |
| SCHEMBL2119327 | 0.72 | MEN1 (0.46) | MEN1ALDH1A1KMT2AKDM4EMAPT | |
| SCHEMBL2119955 | 0.72 | KMT2A (0.43) | MEN1ALDH1A1KMT2AKDM4EMAPT | |
| SCHEMBL2117318 | 0.72 | MEN1 (0.43) | MEN1ALDH1A1KMT2AKDM4EMAPT | |
| SCHEMBL2116719 | 0.72 | P2RX7 (0.39) | MEN1ALDH1A1KMT2AKDM4EMAPT | |
| SCHEMBL2117300 | 0.72 | MAPT (0.46) | MEN1ALDH1A1KMT2AKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095012-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE | ELARA PHARMACEUTICALS GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095012-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE | HIF1A, HIF1AN, EGLN3 | MEN1 3143/4885ALDH1A1 1063/4885KMT2A 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.